FDA Delays AstraZeneca's Breast Cancer Drug Review: What to Know

On May 27, 2026, the FDA announced it has extended its target review date for AstraZeneca's new drug application for camizestrant, a next-generation oral selective estrogen receptor degrader, used in combination with a cyclin-dependent kinase 4/6 inhibitor for first-line treatment of hormone receptor-positive, HER2-negative advanced breast cancer.1 The extension applies specifically to patients whose tumors develop an emergent ESR1 mutation, a genetic change increasingly recognized as a key driver of resistance to standard endocrine therapies.

The delay follows an April 2026 advisory committee meeting in which the FDA's Oncologic Drugs Advisory Committee failed to reach a majority vote supporting the benefit of the proposed treatment strategy.1 That strategy involves monitoring patients for ESR1 mutations in circulating tumor DNA and switching their endocrine backbone therapy upon detection, before radiographic disease progression is evident.

In response to the committee's outcome, AstraZeneca submitted additional analyses to the FDA, including circulating tumor DNA clearance data linked to longer-term efficacy outcomes.1 That data are scheduled to be presented at the American Society of Clinical Oncology annual meeting on June 2, 2026. The FDA's decision to extend the review period reflects its intent to evaluate this supplementary information before reaching a final determination.

Why Does the Regulatory Pathway Here Matter?

One of the most notable aspects of the application is built around a biomarker-driven, adaptive treatment strategy, one where patient selection depends on real-time molecular monitoring rather than a fixed clinical profile at diagnosis.1 Designing and executing pivotal trials around such endpoints introduces complexity in endpoint selection, patient stratification, and data interpretation that regulatory agencies are still working to standardize.

The pivotal SERENA-6 phase 3 trial, which enrolled 315 patients across a globally distributed site network, used investigator-assessed progression-free survival as its primary endpoint.1 Secondary endpoints included overall survival and a second progression-free survival measure. The trial's core innovation, switching therapy based on a detected mutation before visible disease progression, is precisely what made the advisory committee deliberations challenging, as it requires regulators to weigh intermediate biomarker signals against longer-term clinical outcomes data that continues to mature.

The filing also highlights the operational demands of combination drug applications.1 Camizestrant was evaluated alongside three distinct CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. The supporting data package spans multiple combination regimens, each with its own safety and efficacy profile. Managing that breadth across a single regulatory submission is a non-trivial undertaking.

On the international regulatory front, the picture is more advanced.1 The European Medicines Agency's (EMA’s) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval for this indication on May 22, 2026.1 Camizestrant has already received approval in the United Arab Emirates and Saudi Arabia for the same setting, with applications under review in Japan and other markets. The divergence between the European and US regulatory trajectories serves as a reminder that even well-constructed global dossiers can encounter different evidentiary thresholds across jurisdictions, a planning consideration for any development team pursuing simultaneous multinational submissions.

Is the FDA's Extended Review of Camizestrant Part of a Wider Regulatory Pattern?

The camizestrant timeline is not an isolated case.2 In April 2026, the FDA similarly extended its review period for Sanofi's biologics license application for Sarclisa (isatuximab-irfc) subcutaneous formulation, used in combination with standard-of-care regimens for multiple myeloma across all indications currently covered by the existing intravenous formulation.

As with camizestrant, European regulators moved ahead of their US counterparts.2 The CHMP adopted a positive opinion recommending approval of the subcutaneous formulation in late March 2026, with a final decision anticipated in the coming months. Taken together, both cases reinforce a pattern of regulatory agencies navigating increasingly complex applications, and extended review timelines are becoming a more routine feature of the approval landscape for advanced oncology submissions.

References

1. AstraZeneca plc. US FDA decision date on camizestrant extended. Press release. May 27, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/us-fda-decision-date-camizestrant-extended.html
2. Sanofi. Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US. Press release. April 22, 2026. https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-22-05-00-00-3278646